- Home
- BEEP vs CHRS Comparison
BEEP vs CHRS Comparison
Compare BEEP & CHRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BEEP
- CHRS
- Stock Information
- Founded
- BEEP 2015
- CHRS 2010
- Country
- BEEP United States
- CHRS United States
- Employees
- BEEP N/A
- CHRS N/A
- Industry
- BEEP Blank Checks
- CHRS Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- BEEP Finance
- CHRS Health Care
- Exchange
- BEEP Nasdaq
- CHRS Nasdaq
- Market Cap
- BEEP 165.7M
- CHRS 191.3M
- IPO Year
- BEEP N/A
- CHRS 2014
- Fundamental
- Price
- BEEP $3.93
- CHRS $1.39
- Analyst Decision
- BEEP
- CHRS Strong Buy
- Analyst Count
- BEEP 0
- CHRS 4
- Target Price
- BEEP N/A
- CHRS $5.38
- AVG Volume (30 Days)
- BEEP 84.5K
- CHRS 2.0M
- Earning Date
- BEEP 03-13-2025
- CHRS 03-12-2025
- Dividend Yield
- BEEP N/A
- CHRS N/A
- EPS Growth
- BEEP N/A
- CHRS N/A
- EPS
- BEEP N/A
- CHRS N/A
- Revenue
- BEEP $35,743,000.00
- CHRS $304,340,000.00
- Revenue This Year
- BEEP N/A
- CHRS $2.47
- Revenue Next Year
- BEEP N/A
- CHRS N/A
- P/E Ratio
- BEEP N/A
- CHRS N/A
- Revenue Growth
- BEEP 21.33
- CHRS 44.19
- 52 Week Low
- BEEP $2.48
- CHRS $0.66
- 52 Week High
- BEEP $4.86
- CHRS $2.97
- Technical
- Relative Strength Index (RSI)
- BEEP 50.21
- CHRS 45.86
- Support Level
- BEEP $3.42
- CHRS $1.38
- Resistance Level
- BEEP $4.64
- CHRS $1.60
- Average True Range (ATR)
- BEEP 0.38
- CHRS 0.13
- MACD
- BEEP -0.09
- CHRS -0.03
- Stochastic Oscillator
- BEEP 35.92
- CHRS 9.52
About BEEP Mobile Infrastructure Corporation
Mobile Infrastructure Corp focuses on acquiring, owning, and leasing parking facilities and related infrastructure, including parking lots, parking garages and other parking structures throughout the United States. The company owns forty three parking facilities in twenty one separate markets throughout the United States, with a total of approximately fifteen thousand seven hundred parking spaces. The company derives majority of revenue from Percentage rental income.
About CHRS Coherus BioSciences Inc.
Coherus BioSciences Inc is a commercial-stage biopharmaceutical company building an immuno-oncology franchise funded with cash generated by its diversified portfolio of FDA-approved therapeutics. The company is focused on the research, development, and commercialization of its portfolio of FDA-approved oncology products, including LOQTORZI. The company markets UDENYCA, a biosimilar of Neulasta in the United States, and expects to launch the FDA-approved Humira biosimilar YUSIMRY in the United States in 2023. The company generates revenue from the United States.